Kanisa Pharmaceuticals, Inc., based in San Diego, CA, is an oncology-focused specialty pharmaceutical company employing a targeted approach to the diagnosis and treatment of cancer. Kanisa's development strategy combines new treatments for cancer with novel testing formats to stratify patients and predict likely responders to therapy. The company continues to seek late-stage hematology and oncology product licensing opportunities to more fully utilize its infrastructure of very experienced clinical, regulatory, and manufacturing professionals. Kanisa believes that its integrated, targeted approach will maximize treatment benefit to patients, while increasing the efficacy of new and existing drug compounds.